• Takaaki Konuma, Seiko Kato, Jun Ooi, Maki Oiwa-Monna, Yasuhiro Ebihara, Shinji Mochizuki, Koichiro Yuji, Nobuhiro Ohno, Toyotaka Kawamata, Norihide Jo, Kazuaki Yokoyama, Kaoru Uchimaru, Arinobu Tojo, and Satoshi Takahashi.
• Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Electronic address: tkonuma@ims.u-tokyo.ac.jp.
• Biol. Blood Marrow Transplant. 2014 Apr 1; 20 (4): 577-81.

AbstractABO blood group incompatibility between donor and recipient has been associated with poor transplant outcomes in allogeneic hematopoietic stem cell transplantation. However, its effect on the outcome of cord blood transplantation (CBT) has yet to be clarified. We retrospectively analyzed 191 adult patients who received single-unit CBT after myeloablative conditioning for malignant disease in our institute. Major mismatch showed a significantly lower incidence of platelet engraftment compared with ABO match as a reference (hazard ratio, .57; P = .01). Nevertheless, there was no increase in graft-versus-host disease, transplant-related mortality, and overall mortality after ABO-incompatible CBT. These data suggested that donor-recipient ABO incompatibility does not have a significant impact on outcome after myeloablative CBT for hematological malignancies.Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

35 keywords...

hide…